Animal models of human disease in drug safety assessment

Journal of Toxicological Sciences

Volumn 28, Issue 3, 2003, Pages 109-121

  Boelsterli, Urs A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Animal models; Disease models; Idiosyncratic drug toxicity; Susceptibility factors; Toxicity testing; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIVIRUS AGENT; BOSENTAN; BUTHIONINE SULFOXIMINE; CHLORPROMAZINE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FAMOTIDINE; FIALURIDINE; IBUPROFEN; ISONIAZID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; ROSIGLITAZONE; SULFAMETHOXAZOLE; SULFANILAMIDE DERIVATIVE; TACRINE; TOLCAPONE; TROGLITAZONE; XENOBIOTIC AGENT;

CLINICAL TRIAL; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; REVIEW; TOXICITY TESTING; VIRUS INFECTION;

ANIMALIA; RODENTIA;

EID: 0141480136     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.28.109     Document Type: Review

References (77)

1. Andrade, R.J., Lucena, M.I., Garcia-Cortes, M., Garcia-Ruiz, E., Fernandez-Bonilla, E. and Vazquez, L. (2002): Chronic hepatitis C, ibuprofen, and liver damage. Am. J. Gastroenterol., 97, 1854-1855.
2. Barbaro, G., Di Lorenzo, G., Asti, A., Ribersani, M., Belloni, G., Grisorio, B., Filice, G. and Barbarini, G. (1999): Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical findings. Am. J. Gastroenterol., 94, 2198-2205.
3. Barton, C.C., Barton, E.X., Ganey, P.E., Kunkel, S.L. and Roth, R.A. (2000): Bacterial lipopolysaccharide enhances aflatoxin B1 hepatotoxicity in rats by a mechanism that depends on tumor necrosis factor-α. Hepatology, 33, 66-72.
4. Y mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol., 35, 17-23.
5. Berson, A., Renault, S., Letteron, P., Robin, M.A., Fromenty, B., Fau, D., Lebot, M. A., Riche, C., Durand-Schneider, A. M., Feldmann, G. and Pessayre, D. (1996): Uncoupling of rat and human mitochondria: A possible explanation for tacrine-induced liver dysfunction. Gastroenterology, 110, 1878-1890.
6. Boelsterli, U.A. (2002): Mechanisms of NSAID-induced hepatotoxicity - Focus on nimesulide. Drug Safety, 25, 633-648.
7. Boelsterli, U.A. (2003a): Idiosyncratic drug hepatotoxicity revisited: New insights from mechanistic toxicology. Toxicol. Mech. Methods, 13, 3-20.
8. Boelsterli, U.A. (2003b): Disease-related determinants of susceptibility in drug-induced hepatotoxicity. Curr. Opin. Drug Disc. Develop., 6, 81-91.
9. Boelsterli, U.A. and Bedoucha, M. (2002): Toxicological consequences of altered peroxisome proliferator-activated receptor-γ (PPARγ) expression in the liver: Insights from models of obesity and type 2 diabetes. Biochem. Pharmacol., 62, 1-10.
10. Breu, V., Ertel, S. I., Roux, S. and Clozel, M. (1998): The pharmacology of bosentan. Exp. Opin. Invest. Drugs, 7, 1173-1192.
11. Buchweitz, J.P., Ganey, P.E., Bursian, S.J. and Roth, R.A. (2002): Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther, 300, 460-467.
12. Cai, J., Chen, Y., Seth, S., Furukawa, S., Compans, R. W. and Jones, D.P. (2003): Inhibition of influenza infection by glutathione. Free Radic. Biol. Med., 34, 928-936.
13. Caparroz-Assef, S.M., Salgueiro-Pagadigorria, C.L., Bersani-Amado, C.A., Bracht, A., Kelmer-Bracht, A.M. and Ishii-Iwamoto, E.L. (2001): The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats. Cell Biochem. Function, 19, 117-124.
14. Cassarino, D.S. and Bennett, J.P. (1999): An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Rev., 29, 1-25.
15. Chao, L., Marcus-Samuels, B., Mason, M.M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O. and Reitman, M.L. (2000): Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest., 106, 1221-1228.
16. Cheng, P.Y. and Morgan, E.T. (2001): Hepatic cytochrome P450 regulation in disease states. Curr. Drug Metab., 2, 165-183.
17. Cohen, S.M., Robinson, D. and MacDonald, J. (2001): Alternative models for carcinogenicity testing. Toxicol. Sci., 64, 14-19.
18. Davis, R.E., Miller, S., Herrnstadt, C., Ghosh, S.S., Fahy, E., Shinobu, L.A., Galasko, D., Thal, L. J., Beal, M.F., Howell, N. and Parker, W.D. (1997): Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA, 94, 4526-4531.
19. Edvardsson, U., Bergström, M., Alexandersson, M., Bamberg, K., Ljung, B. and Dahllöf, B. (1999): Rosiglitazone (BRL49653), a PPARγ-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J. Lipid Res., 40, 1177-1184.
20. Ellahham, S.H., Charlon, V., Abassi, Z., Calis, K.A. and Choucair, W. K. (2000): Bosentan and the endothelin system in congestive heart failure. Clin. Cardiol., 23, 803-807.
21. El-Serag, H.B. and Everhart, J.E. (2002): Diabetes increases the risk of acute hepatic failure. Gastroenterology, 122, 1822-1828.
22. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B. and Meier, P.J. (2001): The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther., 69, 223-231.
23. Fedatto-Junior, Z., Ishii-Iwamoto, E.L., Caparroz-Assef, S.M., Vicentini, G.E., Bracht, A. and Kelmer-Bracht, A.M. (2002): Glycogen levels and glycogen catabolism in livers from arthritic rats. Mol. Cell. Biochem., 229, 1-7.
24. Festing, M.F.W. (1997): Fat rats and carcinogenesis screening. Nature, 388, 321-322.
25. Gad, S.C. (2002): Drug Safety Evaluation, Wiley-Interscience, New York, N.Y.
26. Guebre-Xabier, M., Yang, S., Lin, H.Z., Schwenk, R., Krzych, U. and Diehl, A.M. (2000): Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage. Hepatology, 31, 633-640.
27. Haasio, K., Koponen, A., Penttila, K.E. and Nissinen, E. (2002): Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol., 453, 21-26.
28. Haskins, J.R., Rowse, P., Rahbari, R. and de la Iglesia, F.A. (2001): Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol., 75, 425-438.
29. Hennet, T., Peterhans, E. and Stocker, R. (1992): Alterations in antioxidant defense in lung and liver of mice infected with influenza A virus. J. Gen. Virol., 73, 39-46.
30. Hewett, J.A. and Roth, R.A. (1993): Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharide. Pharmacol. Rev., 45, 382-411.
31. Hickey, T.E. (1997): Animal care and use in toxicity testing. In Comprehensive Toxicology, Vol. 2., Toxicological Testing and Evaluation (Williams, P. D. and Hottendorf, G. H. eds), pp. 85-100, Elsevier, New York, N.Y.
32. Huang, Y.S., Chern, H.D., Su, W.J., Wu, J. C., Chang, S.C., Chiang, C. H., Chang, F. Y. and Lee, S. D. (2003): Cytochrome P450 2El genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 37, 924-930.
33. Huang, Y.S., Chern, H.D., Su, W. J., Wu,J.C., Lai, S.L., Yang, S.Y., Chang, F.Y. and Lee, S.D. (2002): Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology, 35, 883-889.
34. Ibanez de Caceres, I., Priego, T., Martin, A.I., Lopez-Calderon, A. and Villanua, M.A. (2002): GH administration and renal IGF-I system in arthritic rats. Life Sci., 71, 139-151.
35. Inoue, K., Ogura, A. and Hayashi, J.I. (2002): Production of mitochondrial DNA transgenic mice using zygotes. Methods, 26, 358-363.
36. Ishizuki, S. and Fujihira, E. (1984): Peroxidative status of isolated hepatocytes from adjuvant arthritic rats. Res. Commun. Chem. Pathol. Pharmacol., 44, 431-443.
37. Jia, D.M., Tabaru, A., Akiyama, T., Abe, S. and Otsuki, M. (2000): Troglitazone prevents fatty changes of the liver in obese diabetic rats. J. Gastroenterol. Hepatol., 15, 1183-1191.
38. Kaplowitz, N. (2001): Drug-induced liver disorders. Implications for drug development and regulation. Drug Safety, 24, 483-490.
39. Kumar, U., Dunlop, D.M. and Richardson, J.S. (1994): Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals. Life Sci., 24, 1855-1860.
40. Leclercq, I.A., Field, J. and Farrell, G.C. (2003): Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology, 124, 1451-1464.
41. Levy, M. (1997): Role of viral infections in the induction of adverse drug reactions. Drug Safety, 16, 1-8.
42. Luyendyk, J.P., Maddox, J.F., Cosma, G.N., Ganey, P.E., Cockerell, G.L. and Roth, R.A. (2003): Modest inflammation renders ranitidine hepatotoxic: Is there a relationship to drug idiosyncrasy? Toxicol. Sci., 72 (Suppl. 1), 202.
43. Nishida, T., Huang, T. P., Seiyama, A., Hamada, E., Kamiike, W., Ueshima, S., Kazuo, H. and Matsuda, H. (1998): Endothelin A receptor blockade worsens endotoxin-induced hepatic microcirculatory changes and necrosis. Gastroenterology, 115, 412-420.
44. Ostapowicz, G. and Lee, W.M. (2000): Acute hepatic failure: A Western perspective. J. Gastroenterol. Hepatol., 15, 480-488.
45. Parker, W.D., Boyson, S.J. and Parks, J.K. (1989): Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol., 26, 719-723.
46. Peterhans, E. (1997): Oxidants and antioxidants in viral diseases: Disease mechanisms and metabolic regulation. J. Nutr., 127, S962-S965.
47. Rashid, A., Wu, T.C., Huang, C.C., Chen, C.H., Lin, H.Z., Yang, S.Q., Lee, F.Y.J. and Diehl, A.M. (1999): Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology, 29, 1131-1138.
48. Reed, M.J., Meszaros, K., Entes, L.J., Claypool, M.D., Pinkett, J.G., Gadbois, T.M. and Reaven, G.M. (2000): A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism, 49, 1390-1394.
49. Rehman, A., Nourooz-Zadeh, J., Möller, W., Trischler, H., Pereira, P. and Halliwell, B. (1999): Increased oxidative damage to all DNA bases in patients with type II diabetes mellitus. FEBS Lett., 448, 120-122.
50. Renton, K.W. and Armstrong, S.G. (1994): Immune-mediated downregulation of cytochrome-P450 and related drug biotransformation. In Immunotoxicology and Immunopharmacology, Second Edition (Dean, J.H., Luster, M.I., Munson, A.E. and Kimber, I., eds.), pp. 501-512, Raven Press, New York, NY.
51. Rieder, M.J., Krause, R., Bird, I.A. and Dekaban, G.A. (1995): Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and non-infected cells. J. AIDS, 8, 134-140.
52. Riley, T.R. and Smith, J.P. (1998): Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: A case series. Am. J. Gastroenterol., 93, 1563-1565.
53. Robertson, D.G., Braden, T.K., Urda, E.R., Lalwani, N.D. and de la Iglesia, F.A. (1998): Elucidation of mitochondrial effects by tetrahydroaminoacridine (tacrine) in rat, dog, monkey and human hepatic parenchymal cells. Arch. Toxicol., 72, 362-371.
54. Rodriquez, L.A.G., Williams, R., Derby, L.E., Dean, A.D. and Jick, H. (1994): Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch. Intern Med, 154, 311-316.
55. Roth, R.A., Harkema, J.R., Pestka, J.P. and Ganey, P.E. (1997): Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol. Appl. Pharmacol., 147, 300-311.
56. Roubenoff, R., Freedman, L.M., Smith, D.E., Abad, L.W., Dinarello, C.A. and Kehayias, J.J. (1997): Adjuvant arthritis as a model of inflammatory cachexia. Arthritis Rheum., 40, 534-539.
57. Rudmann, D.G. and Durham, S.K. (1999): Utilization of genetically altered animals in the pharmaceutical industry. Toxicol. Pathol., 27, 111-114.
58. Rudolph, U. and Moehler, H. (1999): Genetically modified animals in pharmacological research: Future trends. Eur. J. Pharmacol., 375, 327-337.
59. 4-induced hepatotoxicity in type 2 diabetes: Role of tissue repair. Toxicol. Sci., 72 (Suppl. S-1), 197.
60. Sharyo, S., Sagisaka, H., Tanaka, K., Ogata, S., Furukawa, T., Takaoka, M. and Manabe, S. (2001): Troglitazone, pioglitazone and rosiglitazone induce fatty changes in the liver in db/db mice. Toxicol. Sci., 60 (Suppl.), 349.
61. Shedlofsky, S.I., Israel, B.C., McClain, C.J., Hill, D.B. and Blouin, R.A. (1994): Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Invest., 94, 2209-2214.
62. Sigthorsson, G., Simpson, R. J., Walley, M., Anthony, A., Foster, R., Hotz-Behoftsitz, C., Palizban, A., Pombo, J., Watts, J., Morham, S.G. and Bjarnason, I. (2002): COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal antiinflammatory drug enteropathy in mice. Gastroenterology, 122, 1913-1923.
63. Smith, K.S., Smith, P.L., Heady, T.N., Trugman, J.M., Harman, W.D. and Macdonald, T.L. (2003): In vitro metabolism of tolcapone to reactive intermediates: Relevance to tolcapone liver toxicity. Chem. Res. Toxicol., 16, 123-128.
64. Spaniol, M., Brooks, H., Auer, L., Zimmermann, A., Solioz, M., Stieger, B. and Krähenbühl, S. (2001): Development and characterization of an animal model of carnitine deficiency. Eur. J. Biochem., 268, 1876-1887.
65. Stevens, D.A. (1996): Animal models in the evaluation of antifungal drugs. J. Mycol. Med., 6 (Suppl. 1), 7-10.
66. Suzuki, S., Hinokio, Y., Komatu, K., Ohtomo, M., Onoda, M., Hirai, S., Hirai, M., Hirai, A., Chiba, M., Kasuga, S., Akai, H. and Toyota, T. (1999): Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res. Clin. Pract., 45, 161-168.
67. Swerdlow, R.H., Parks, J.K., Miller, S W., Tuttle, J.B., Trimmer, P.A., Sheehan, J.P., Bennett, J.P., Davis, R.E. and Parker, W.D. (1996): Origin and functional consequences of the complex I defect in Parkinson's disease. Annals Neurol., 40, 663-671.
68. Tanaka, K., Higuchi, H., Karasawa, F. and Sato, T. (1999): Effects of selective and non-selective endothelin antagonists on ischemia-reperfusion damage in the isolated perfused murine liver. Res. Commun. Chem. Pathol. Pharmacol., 103, 129-138.
69. Tennant, B.C., Baldwin, B.H., Graham, L.A., Ascenzi, M.A., Hornbuckle, W.E., Rowland, P.H., Tochkov, I.A., Yeager, A.E., Erb, H.N., Colacino, J. M., Lopez, C., Engelhardt, J. A., Bowsher, R.R., Richardson, F.C., Lewis, W., Cote, P.J., Korba, B.E. and Gerin, J.L. (1998): Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology, 28, 179-191.
70. Thomas, J.A. (1997): Use of animal models in biomedical research. In Comprehensive Toxicology, Vol. 2, Toxicological Testing and Evaluation (Williams, P.D. and Hottendorf, G.H., eds.), pp. 227-238, Elsevier, New York, N.Y.
71. Wallace, D.C. (2001): Mouse models for mitochondrial disease. Am. J. Med. Genet., 106, 71-93.
72. Watkins, S.M., Reifsnyder, P.R., Pan, H., German, J.B. and Leiter, E.H. (2002): Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. J. Lipid Res., 43, 1809-1817.
73. Weinstock, R.S., Murray, F.T., Diani, A., Sangani, G.A., Wachowski, M.B. and Messina, J.L. (1997): Pioglitazone: In vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAY mice. Pharmacology, 54, 169-178.
74. Yamaguchi, Y., Tanaka, Y., Yamada, K., Bando, Y. and Kunitomo, M. (1989): Abnormal lipid metabolism in adjuvant arthritic rats. Jpn. J. Pharmacol., 50, 377-386.
75. Yang, S.Q., Lin, H.Z., Lane, M.D., Clemens, M. and Diehl, A.M. (1997): Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. USA, 94, 2557-2562.
76. Yang, S.Q., Lin, H.Z., Mandal, A.K., Huang, J. and Diehl, A.M. (2001): Disrupted signaling and inhibited regeneration in obese mice with fatty liver: Implications for nonalcoholic fatty liver disease pathophysiology. Hepatology, 34, 694-706.
77. Zbinden, G. (1987): Predictive value of animal studies in toxicology. CMR Annual Lecture. Centre for Medicines Research, White Crescent Press, Luton, U.K.